Ken Griffin
LEGN icon

Ken Griffin’s Legend Biotech LEGN Stock Holding History

Ken Griffin’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.35M Buy
516,980
+338,940
+190% +$6.46M ﹤0.01% 3351
2025
Q4 		$3.87M Sell
178,040
-204,772
-53% -$5.87M ﹤0.01% 4720
2025
Q3 		$12.5M Buy
382,812
+217,751
+132% +$8.04M ﹤0.01% 2935
2025
Q2 		$5.86M Buy
165,061
+9,887
+6% +$320K ﹤0.01% 3842
2025
Q1 		$5.27M Sell
155,174
-2,749,683
-95% -$98.6M ﹤0.01% 3780
2024
Q4 		$94.5M Buy
2,904,857
+1,588,303
+121% +$65.8M 0.02% 768
2024
Q3 		$64.2M Sell
1,316,554
-128,309
-9% -$6.83M 0.01% 1008
2024
Q2 		$64M Buy
1,444,863
+300,387
+26% +$13.9M 0.01% 959
2024
Q1 		$64.2M Buy
1,144,476
+978,545
+590% +$59M 0.01% 1025
2023
Q4 		$9.98M Buy
165,931
+144,476
+673% +$9.16M ﹤0.01% 2846
2023
Q3 		$1.44M Sell
21,455
-17,357
-45% -$1.21M ﹤0.01% 5844
2023
Q2 		$2.68M Buy
38,812
+31,511
+432% +$2.06M ﹤0.01% 4652
2023
Q1 		$352K Sell
7,301
-24,192
-77% -$1.18M ﹤0.01% 9035
2022
Q4 		$1.57M Sell
31,493
-226,783
-88% -$11M ﹤0.01% 5940
2022
Q3 		$10.5M Buy
258,276
+137,467
+114% +$6.45M ﹤0.01% 2686
2022
Q2 		$6.64M Buy
120,809
+44,044
+57% +$1.86M ﹤0.01% 3296
2022
Q1 		$2.79M Buy
76,765
+53,585
+231% +$2.12M ﹤0.01% 5364
2021
Q4 		$1.08M Sell
23,180
-140,745
-86% -$7.14M ﹤0.01% 7758
2021
Q3 		$8.29M Buy
163,925
+107,964
+193% +$4.49M ﹤0.01% 3395
2021
Q2 		$2.3M Sell
55,961
-540,753
-91% -$18.4M ﹤0.01% 6250
2021
Q1 		$17.3M Buy
596,714
+360,065
+152% +$9.82M ﹤0.01% 2154
2020
Q4 		$6.66M Sell
236,649
-68,527
-22% -$1.97M ﹤0.01% 3200
2020
Q3 		$9.42M Buy
305,176
+274,817
+905% +$9.25M ﹤0.01% 2356
2020
Q2 		$1.29M Buy
+30,359
New +$1.19M ﹤0.01% 5355

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.44B AUM 18.47% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ken Griffin's LEGN Position: Q1 2026 in Review

Ken Griffin increased its Legend Biotech (LEGN) stake by 190% in Q1 2026, buying an estimated $6.46M and bringing the position to 516,980 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

Ken Griffin first reported a position in LEGN in Q2 2020 and has held it in 24 quarters since. The position peaked at $94.5M in Q4 2024. 191 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Ken Griffin held 516,980 shares of Legend Biotech worth $9.35M as of Q1 2026.
  • Ken Griffin bought 338,940 Legend Biotech shares in Q1 2026, an estimated $6.46M.
  • Legend Biotech made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3351 holding.
  • Ken Griffin first reported a position in Legend Biotech in Q2 2020 and has held it in 24 quarters since.
  • Ken Griffin's Legend Biotech position peaked at $94.5M in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.